Warning - to ADHD Drug Strattera

Drug Strattera:" The FDA has issued a public health advisory reports of suicidal thinking in children and adolescents - Strattera, a drug to treat (ADHD) in adults and children.The FDA has ordered Strattera's maker, Eli Lilly and Co., to revise this product to include a "black box" warning on Strattera's product label and additional warning statements that alert health care providers of the increased risk of suicidal thinking. A black box warning is the strongest type of warning that the FDA can require for a drug. It is generally reserved for warning prescription drug users about adverse drug reactions that can cause serious injury or death. Strattera is the first FDA-approved nonstimulant to treat ADHD. Strattera has been on the market since 2002 and has been used by more than 2 million patients, according to the FDA. Strattera should be stopped in patients with signs of jaundice yellowing of the skin or whites of the eyes. Jaundice is a sign of liver damage. If blood tests show evidence of liver damage, the drug should also be stopped. In addition to yellowing of the whites of the eyes or the skin, there are other signs of liver damage. If you also notice any of these while taking Strattera, let your doctor know immediately. (Itchy skin,Dark urine,Pain or tenderness in the upper, right side of the abdomen,Unexplained "flu-like" symptoms.)"